ARO-INHBE
PreclinicalSmall molecule
Arrowhead PharmaceuticalsARO-INHBE is one of 47 small molecule programs targeting Obesity. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
Retatrutide
Eli LillyPhase 3
NNC0487-0111
Novo NordiskPhase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Berobenatide
PfizerPhase 3
Zenagamtide
Novo NordiskPhase 3
Ribupatide
KKailera
Phase 3
Elecoglipron
AstraZenecaPhase 3
PF-08653944
PfizerPhase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARO-INHBE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company